X0206 3 2019-09-12 0 0001692830 Satsuma Pharmaceuticals, Inc. STSA 0001391070 Kollins John A SATSUMA PHARMACEUTICALS, INC. 400 OYSTER POINT BOULEVARD, SUITE 221 SOUTH SAN FRANCISCO CA 94080 1 1 0 0 President and CEO Common Stock, $0.0001 par value 305911 D Stock Option (Right to Buy) 0.90 2027-01-18 Common Stock 92805 D Stock Option (Right to Buy) 0.90 2027-04-19 Common Stock 13297 D Stock Option (Right to Buy) 1.04 2028-05-01 Common Stock 109042 D Stock Option (Right to Buy) 4.56 2029-05-16 Common Stock 266176 D Reflects a 1-for-4.7 reverse stock split effective upon the effectiveness of the registration statement for the Issuer's initial public offering. A portion of these shares is subject to a right of repurchase held by the Issuer. The original grant was for 127,659 shares, of which 34,854 shares have been exercised and are included in Table I. A portion of the remaining shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: Twenty Five Percent (25%) of the shares subject to the option vest one year measured from January 18, 2017 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. The original grant was for 127,659 shares, of which 114,361 shares have been exercised and are included in Table I. A portion of the remaining shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares vested as to twenty five percent (25%) of the shares upon achievement of a qualified financing on December 16, 2016 and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. The original grant was for 127,659 shares, of which 18,617 shares have been exercised and are included in Table I. A portion of the remaining shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: Twenty Five Percent (25%) of the shares subject to the option vest one year measured from January 18, 2017 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. The original grant was for 276,595 shares, of which 10,418 shares have been exercised and are included in Table I. A portion of the remaining shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from May 15, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. /s/ Thomas P. O'Neil as Attorney in Fact for John A. Kollins 2019-09-12